For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and the formulated version represents a significant change. These groundbreaking therapies protect the transthyretin protein, slowing its destructive build-up and redu